Curocell Inc. (372320.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩24,400 (+4.72%) as of
Key statistics
- Market cap
- 371.51B
- Dividend yield
- 0.00%
- 52-week range
- 20,650.00 – 66,000.00
- Beta
- 0.80
- Profit margin
- 0.00%
- Volume
- 29.11k
About Curocell Inc.
Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Daejeon, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.